Skip to main content
Vita 34 AG logo

Vita 34 AG — Investor Relations & Filings

Ticker · V3V ISIN · DE000A0BL849 LEI · 529900OEWA4GSZEZ4P40 F Human health and social work activities
Open in API
Filings indexed 794 across all filing types
Latest filing 2017-06-16 Declaration of Voting R…
Country DE Germany
Listing F V3V

About Vita 34 AG

https://www.vita34.de/en/

Vita 34 AG is a biobank specializing in the cryopreservation of stem cells derived from umbilical cord blood and tissue. Established in 1997 as the first private cord blood bank in Europe, the company offers services for the long-term storage of perinatal stem cells for potential future medical applications. The service portfolio includes providing collection kits for childbirth, handling logistics, processing the biological material, and storing the stem cell deposits under cryogenic conditions. These services are offered to expectant parents as a form of private medical provision for their child and family. As part of the Famicord Group, Vita 34 is also involved in research and development related to cell-based therapies.

Recent filings

Filing Released Lang Actions
Release according to Article 26a of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled 'Vita 34 AG: Release according to Article 26a of the WpHG' and specifically announces the 'Publication of total number of voting rights' as of June 16, 2017. It details a capital measure ('Other capital measure' under Sec. 26a para. 1 WpHG) and states the 'New total number of voting rights: 3329149'. This content directly relates to the official declaration of voting results or rights announcements following a corporate action or as a regulatory requirement. This aligns best with the definition for 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not a general earnings release (ER), a full annual report (10-K), or a simple dividend notice (DIV).
2017-06-16 English
Vita 34 AG acquires MK Beleggingsmaatschappij Venlo B.V. as a new strategic investor and secures support for further corporate action
Capital/Financing Update Classification · 98% confidence The document is a news release disseminated via DGAP, announcing that Vita 34 AG has acquired a new strategic investor (MK Beleggingsmaatschappij Venlo B.V.) and secured support for an upcoming rights issue (a capital increase). This announcement details the acquisition of shares by an external entity and the agreement for a backstop obligation related to future financing. This activity directly relates to changes in the company's capital structure and fundraising efforts. Therefore, the most appropriate classification is 'Capital/Financing Update' (CAP). It is not an Earnings Release (ER), Interim Report (IR), or a formal regulatory filing like a 10-K, but rather a specific announcement about a financing/investment event.
2017-06-14 English
Vita 34 AG decides on a capital increase of around 10%
Capital/Financing Update Classification · 99% confidence The document is an 'Ad-hoc' announcement dated June 13, 2017, explicitly stating that 'Vita 34 AG decides on a capital increase of around 10%'. It details the exclusion of subscription rights, the issuance of new shares, the issue price, and the intended use of proceeds (financing an acquisition). This content directly relates to changes in the company's capital structure and fundraising activities. This aligns perfectly with the definition for 'Capital/Financing Update' (Code: CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific corporate finance action.
2017-06-13 English
Vita 34 AG updates on planned capital increase and changes in the management
Share Issue/Capital Change Classification · 99% confidence The document is an 'Ad-hoc' disclosure dated June 12, 2017, classified under 'Disclosure of an inside information acc. to Article 17 MAR'. It details two major corporate actions: a planned capital increase (financing activity) and immediate changes in the Management Board (personnel change). Since it covers both capital structure changes (CAP) and management changes (MANG), I must select the most encompassing or primary theme, or check if a specific code covers combined announcements. The text explicitly mentions both 'planned capital increase' and 'changes in the management'. The filing type 'CAP' covers financing activities, and 'MANG' covers management changes. Since this is a mandatory disclosure of material, non-public information (inside information) regarding significant corporate events, and it is not a standard periodic report (10-K, IR) or a simple announcement of a report (RPA), it fits best as a general regulatory filing or one of the specific corporate actions. Given the dual nature, and that these are often released together as material updates, I will check the definitions. 'CAP' (Capital/Financing Update) and 'MANG' (Board/Management Information) are both relevant. However, the document is structured as an immediate disclosure of material events under MAR, which often falls under the general 'Regulatory Filings' (RNS) if a more specific code doesn't perfectly capture the combination, or if the primary focus is regulatory compliance. Since it details specific corporate actions (financing and personnel), and there isn't a combined code, I will prioritize the most significant corporate action or use the fallback. The financing aspect (capital increase) is detailed extensively. However, the document is a direct disclosure of inside information, which is a type of regulatory announcement. Given the options, and the fact that it is a direct, immediate disclosure of material events rather than a standard periodic report, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is a strong candidate. Alternatively, since it heavily features a capital increase, 'CAP' is plausible. Since it is an 'Ad-hoc' disclosure of inside information covering multiple material events (financing and management changes), 'RNS' serves as the best general regulatory category for such immediate, non-periodic disclosures that don't fit perfectly elsewhere, although 'CAP' is also strongly supported by the content. I will classify it as 'RNS' as it is a direct MAR disclosure of inside information, which is a broad regulatory filing category, or 'CAP' due to the detailed financing plan. Given the explicit mention of 'Corporate Action/Change of Personnel' in the keywords, and the detailed plan for capital increase, 'CAP' seems slightly more specific than the general 'RNS' fallback, even with the management change included. Let's re-evaluate: The document announces both a capital increase (CAP) and management changes (MANG). In many contexts, a combined announcement like this defaults to the most significant regulatory filing type or the general regulatory category. Since it is an 'Ad-hoc' disclosure under MAR, 'RNS' is appropriate for immediate regulatory news. I will select RNS as the most accurate classification for an immediate, mandatory disclosure of inside information covering multiple material events.
2017-06-12 English
Vita 34 AG has a Successful Start in Current Fiscal Year 2017
Earnings Release Classification · 100% confidence The document is titled 'Vita 34 AG has a Successful Start in Current Fiscal Year 2017' and explicitly mentions 'Quarter Results' and provides key financial metrics for the 'first three months of 2017' (Revenues, EBITDA, costs). This content strongly indicates a report summarizing performance for a period shorter than a full year. The text also states, 'The complete quarterly report for the first three months of 2017 is available immediately for download...'. Because this document summarizes the results and points to the full report, it fits the definition of an Earnings Release (ER) which provides initial key highlights, or potentially an Interim Report (IR) if it were the comprehensive document. Given the structure (news release format, key highlights, and reference to the 'complete quarterly report'), it is best classified as an Earnings Release (ER). It is not a Report Publication Announcement (RPA) because it contains substantial financial data, not just a notice of publication. Q1 2017
2017-05-16 English
Q1 statement / Q1 financial report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report January to March 2017' and contains comprehensive financial statements, including a condensed consolidated statement of income, key financial figures, and management discussion of business performance for the first quarter. It is not an announcement of a report, but the report itself, containing substantive financial data for a period shorter than a full fiscal year. Q1 2017
2017-05-16 German

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.